Haemonetics Corporation

Company profile

Global medical technology company focused on improving the quality, effectiveness and efficiency of health care.
Business organized into three principal reporting segments: Plasma, Blood Center and Hospital.
Headquarters: Boston, Massachusetts (125 Summer Street).
Primary manufacturing in the U.S. and abroad; products shipped to approximately 90 countries.

Automated plasma collection systems and disposables: NexSys PCS plasmapheresis system; NexSys PCS with Persona technology; Persona PLUS introduced in 2026; Express Plus enhancements in 2024.
Donor management and support software: NexLynk DMS donor management system; Donor360 tools.
NexLynk DMS connects to NexSys PCS and automates donation procedures and data capture.
Focused on source plasma collection for pharmaceutical manufacturers, emphasizing high-yield, efficient collections.

Automated blood component collection systems: MCS brand apheresis equipment; ACP automated cell processor; NexSys PCS for plasma collections.
Divested Whole Blood line in 2025 to concentrate on higher-margin opportunities.
Primarily serves blood centers and other blood collectors.

Interventional Technologies: VASCADE family (vascular closure), PerQseal Elite large-bore closure (added via acquisition), Sensor-Guided Technologies (OptoWire, SavvyWire), Esophageal Protection (ensoETM).
Blood Management Technologies: Hemostasis Management (TEG 6s system and TEG Manager software), Cell Salvage (Cell Saver Elite+), Transfusion Management (SafeTrace Tx, BloodTrack).
Recent activity includes the 2026 acquisition of Vivasure Medical Limited and labeling expansions such as VASCADE MVP XL indications.

Operations in approximately 90 countries; direct sales force plus independent distributors in about 87 countries.
Ten largest customers accounted for about 44% of net revenues in fiscal 2026.
In Plasma, one customer accounted for about 13% of total net revenues in fiscal 2026.
Customer base includes biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

Net revenues: $1,334,027 thousand in 2026; $1,360,824 thousand in 2025.
Gross profit: $787,586 thousand in 2026; $748,958 thousand in 2025.
- Gross margin: 59.0% in 2026 vs 55.0% in 2025.
Operating expenses: $630,852 thousand in 2026; $527,141 thousand in 2025.
Operating income: $156,734 thousand in 2026; $221,817 thousand in 2025.
Interest and other expense, net: $(28,704) thousand in 2026; $(9,746) thousand in 2025.
Income before taxes: $128,030 thousand in 2026; $212,071 thousand in 2025.
Provision for income taxes: $30,722 thousand in 2026; $44,392 thousand in 2025.
Net income: $97,308 thousand in 2026; $167,679 thousand in 2025.
Net income per share (basic): $2.06 in 2026; $3.33 in 2025.
Net income per share (diluted): $2.05 in 2026; $3.31 in 2025.
End of fiscal year 2026 headcount: 3,009 full-time equivalent employees.
Stockholders of record: 93 as of March 28, 2026.

Cash and cash equivalents: $245.4 million as of March 28, 2026.
Availability under revolving credit facilities: $448.7 million.
Net debt position: approximately -$979.1 million (cash greater than total debt).
Debt outstanding (as of March 28, 2026):
- Term loan under 2024 Revised Credit Facilities: $239.1 million
- 2029 Convertible Notes: $700.0 million
- Revolving credit facility: $300.0 million outstanding
Total liquidity supports acquisitions, investments, capital expenditures, share repurchases and debt service.

Acquisition: Vivasure Medical Limited completed January 9, 2026 for a net purchase price of $164.4 million; adds PerQseal Elite large-bore vascular closure.
Share repurchases: ongoing three-year program with activity in 2025 and 2026, including an accelerated share repurchase and Rule 10b5-1 plans; total remaining authorization was $325.0 million as of March 28, 2026.
Conversions and debt actions: repaid 2026 Notes at maturity ($300.0 million) in March 2026; 2029 convertible notes remain outstanding with conversion features and related risks; capped call transactions related to prior debt issuances expired with the note maturity.

Emphasis on higher-margin Plasma and Hospital offerings and ongoing portfolio rationalization.
Global manufacturing footprint with multiple locations; reliance on some single-source suppliers and contract sterilization, with ongoing supply chain and inflation considerations.
Continued investment in R&D focused on plasma technologies and hospital solutions; compliance with regulatory requirements and quality management systems.